Alector publishes corporate deck highlighting Brain Carrier platform and neurodegenerative disease pipeline

Alector outlined a brain-carrier pipeline led by AL137, an anti-amyloid beta antibody program targeting subcutaneous dosing and reduced ARIA, anemia, and infusion-reaction risk.

AL137 timeline targets first-in-human studies in 2027, following non-human primate IND-enabling work in 2026.

Preclinical data showed AL137 reached 8.4 nM in non-human primate frontal cortex at 3 mg/kg, cited as 32x higher than a non-carrier comparator.

The clinical plan calls for a Phase 1a single-ascending-dose study in healthy volunteers, followed by a Phase 1b multiple-ascending-dose study in early Alzheimer’s patients.

Other disclosed programs target first-in-human studies from 2027 to 2028, including tau, alpha-synuclein, and NLRP3 siRNA candidates.